John Maraganore
E446842
John Maraganore is a biotechnology executive best known as the founding CEO of Alnylam Pharmaceuticals and a pioneer in the development of RNA interference (RNAi) therapeutics.
All labels observed (1)
| Label | Occurrences |
|---|---|
| John Maraganore canonical | 3 |
How this entity was disambiguated
This entity first appeared as the object of triple T4492399 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: John Maraganore Context triple: [Alnylam Pharmaceuticals, foundedBy, John Maraganore]
-
A.
John Norville
John Norville is a screenwriter best known for co-writing the story for Disney's adventure film "Jungle Cruise."
-
B.
John Dunlavy
John Dunlavy was an early 19th-century American religious leader and writer involved in the dissolution of the Springfield Presbytery and later known for his association with the Shaker movement.
-
C.
William Hathaway
William Hathaway was a Democratic U.S. Senator and Representative from Maine who served in Congress during the 1960s and 1970s.
-
D.
Tom Hickey
Tom Hickey was an Irish actor known for his extensive work in theatre, film, and television, particularly in Ireland.
-
E.
Greg Hoblit
Greg Hoblit is an American film and television director and producer known for his work on acclaimed series like "Hill Street Blues" and films such as "Primal Fear" and "Frequency."
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: John Maraganore Target entity description: John Maraganore is a biotechnology executive best known as the founding CEO of Alnylam Pharmaceuticals and a pioneer in the development of RNA interference (RNAi) therapeutics.
-
A.
John Norville
John Norville is a screenwriter best known for co-writing the story for Disney's adventure film "Jungle Cruise."
-
B.
John Dunlavy
John Dunlavy was an early 19th-century American religious leader and writer involved in the dissolution of the Springfield Presbytery and later known for his association with the Shaker movement.
-
C.
William Hathaway
William Hathaway was a Democratic U.S. Senator and Representative from Maine who served in Congress during the 1960s and 1970s.
-
D.
Tom Hickey
Tom Hickey was an Irish actor known for his extensive work in theatre, film, and television, particularly in Ireland.
-
E.
Greg Hoblit
Greg Hoblit is an American film and television director and producer known for his work on acclaimed series like "Hill Street Blues" and films such as "Primal Fear" and "Frequency."
- F. None of above. chosen
Statements (30)
| Predicate | Object |
|---|---|
| instanceOf |
biotechnology executive
ⓘ
businessperson ⓘ chief executive officer ⓘ |
| associatedWith |
Alnylam Pharmaceuticals leadership team
ⓘ
linked to:
Alnylam Pharmaceuticals
RNAi therapeutics field ⓘ |
| employer | Alnylam Pharmaceuticals ⓘ |
| field |
RNA interference therapeutics
ⓘ
biotechnology ⓘ pharmaceutical industry ⓘ |
| hasExpertise |
RNA interference
ⓘ
biopharmaceutical company building ⓘ drug development ⓘ |
| hasReputation |
leader in biotechnology entrepreneurship
ⓘ
pioneer in RNAi therapeutics ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| knownFor |
founding CEO of Alnylam Pharmaceuticals
ⓘ
leadership in RNAi drug development ⓘ pioneering RNA interference therapeutics ⓘ |
| nationality | American ⓘ |
| notableFor | helping translate RNAi biology into approved drugs ⓘ |
| notableWork |
advocacy for RNAi as a new class of medicines
ⓘ
development of RNAi-based medicines ⓘ |
| occupation |
biotechnology executive
ⓘ
corporate director ⓘ |
| positionHeld |
Board member at multiple biotechnology companies
ⓘ
Chief Executive Officer of Alnylam Pharmaceuticals ⓘ founding CEO of Alnylam Pharmaceuticals ⓘ |
| roleIn |
commercialization of RNAi therapeutics
ⓘ
strategic direction of Alnylam Pharmaceuticals ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: John Maraganore Description of subject: John Maraganore is a biotechnology executive best known as the founding CEO of Alnylam Pharmaceuticals and a pioneer in the development of RNA interference (RNAi) therapeutics.
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject linked to:
ALNY